ZENTALIS PHARMACEUTICALS INC (ZNTL)
US98943L1070 - Common Stock
ZNTL gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While ZNTL has a great health rating, there are worries on its profitability. ZNTL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ZNTL has reported negative net income.
In the past year ZNTL has reported a negative cash flow from operations.
ZNTL had negative earnings in each of the past 5 years.
ZNTL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ZNTL has a Return On Assets (-39.78%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -50.60%, ZNTL is doing good in the industry, outperforming 66.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.78% | ||
| ROE | -50.6% | ||
| ROIC | N/A |
ROA(3y)-43.93%
ROA(5y)-43.24%
ROE(3y)-55.01%
ROE(5y)-55.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ZNTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ZNTL has been increased compared to 1 year ago.
The number of shares outstanding for ZNTL has been increased compared to 5 years ago.
ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ZNTL has an Altman-Z score of -2.32. This is a bad value and indicates that ZNTL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.32, ZNTL is in line with its industry, outperforming 51.42% of the companies in the same industry.
There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.32 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ZNTL has a Current Ratio of 7.29. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.29, ZNTL is doing good in the industry, outperforming 69.04% of the companies in the same industry.
ZNTL has a Quick Ratio of 7.29. This indicates that ZNTL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.29, ZNTL is in the better half of the industry, outperforming 69.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.29 | ||
| Quick Ratio | 7.29 |
3. Growth
3.1 Past
ZNTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.06%, which is quite impressive.
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, ZNTL will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.03% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.04%
EPS Next 2Y16.47%
EPS Next 3Y11.26%
EPS Next 5Y12.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ZNTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ZNTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.47%
EPS Next 3Y11.26%
5. Dividend
5.1 Amount
No dividends for ZNTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ZENTALIS PHARMACEUTICALS INC
NASDAQ:ZNTL (12/20/2024, 8:00:02 PM)
After market: 3 0 (0%)3
+0.07 (+2.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners108.18%
Inst Owner Change-10.45%
Ins Owners3.12%
Ins Owner Change4.91%
Market Cap213.81M
Analysts77.65
Price Target9.69 (223%)
Short Float %6.81%
Short Ratio3.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-44.57%
Max EPS beat(2)39.67%
EPS beat(4)3
Avg EPS beat(4)28.36%
Min EPS beat(4)-44.57%
Max EPS beat(4)117.9%
EPS beat(8)5
Avg EPS beat(8)8.21%
EPS beat(12)7
Avg EPS beat(12)7.99%
EPS beat(16)8
Avg EPS beat(16)3.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.04%
PT rev (3m)-4.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.74%
EPS NY rev (1m)18.09%
EPS NY rev (3m)18.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.6 | ||
| P/tB | 0.61 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.59
EYN/A
EPS(NY)-2.99
Fwd EYN/A
FCF(TTM)-2.42
FCFYN/A
OCF(TTM)-2.41
OCFYN/A
SpS0.57
BVpS4.97
TBVpS4.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.78% | ||
| ROE | -50.6% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-43.93%
ROA(5y)-43.24%
ROE(3y)-55.01%
ROE(5y)-55.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 30.1% | ||
| Cap/Sales | 0.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.29 | ||
| Quick Ratio | 7.29 | ||
| Altman-Z | -2.32 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)450.59%
Cap/Depr(5y)428.99%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.11%
EPS Next Y46.04%
EPS Next 2Y16.47%
EPS Next 3Y11.26%
EPS Next 5Y12.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.58%
EBIT Next 3Y2.01%
EBIT Next 5YN/A
FCF growth 1Y-2.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.09%
OCF growth 3YN/A
OCF growth 5YN/A